PharmacyPharmacologyPharmacotherapyAllergyAntimicrobial PharmacotherapyClinical PharmacologyAdverse Drug Event PreventionAntiarrhythmic TherapyDrug AllergyAntihistamine AppropriatenessAntihistamine PharmacologyAntihistamine PremedicationAntihistamine TreatmentQt Interval AnalysisQt Interval AssessmentSedating AntihistaminesSide Effect Profile
The United States Food and Drug Administration (FDA) has announced that it plans to ban terfenadine, a popular antihistamine which has been on the market since 1985. In 1992, however, it became known that terfenadine may cause prolongation of the QT interval and trigger fatal ventricular arrhythmias. This side effect is seen when the drug is taken concomitantly with the antibiotics erythromycin and clarithromycin and with the antifungals ketoconazole …